View More Recent Stories

Jan 6, 2025 07:09AM H.C. Wainwright Reiterates Buy Rating on Alumis Inc (ALMS)

Dec 19, 2024 08:00AM Alumis (ALMS) Announces Positive Phase 1 Data for A-005

Nov 14, 2024 06:58AM Alumis Inc (ALMS) PT Lowered to $26 at H.C. Wainwright

Oct 30, 2024 04:08PM Baird Starts Alumis Inc (ALMS) at Outperform

Oct 17, 2024 09:22AM H.C. Wainwright Starts Alumis Inc (ALMS) at Buy

Sep 27, 2024 09:00AM Alumis (ALMS) Reports ESK-001 Demonstrated Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Jul 29, 2024 08:04AM Alumis (ALMS) Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 23, 2024 06:31AM Cantor Fitzgerald Starts Alumis Inc (ALMS) at Overweight

Jul 23, 2024 03:27AM Morgan Stanley Starts Alumis Inc (ALMS) at Overweight

Jun 28, 2024 12:42PM Alumis (ALMS) Opens At $13.50, IPO Priced At $16

Jun 28, 2024 05:50AM Alumis (ALMS) Prices 13.125M Share IPO at $16/sh

Jun 24, 2024 06:42AM Alumis (ALMS) Announces 17.65M Share IPO at $16-$18/sh

Jun 18, 2024 06:08AM Alumis (ALMS) files for proposed IPO

View More Recent Stories